Total Live Articles: 402

Atopic Dermatitis (Eczema)

NICE guideline [CG57] Atopic eczema in under 12s: diagnosis and management. Last updated: Sep 2025.

NICE CKS Eczema – atopic. Last revised: Mar 2025.

Atopic Dermatitis (Eczema)

Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterised by dry, itchy skin and an episodic course of flares and remission.

This updated UKMLA guide to atopic dermatitis is based on NICE CG57 and NICE CKS, which covers causes, risk factors, symptoms, complication, diagnosis, and management.

Epidemiology

Atopic dermatitis can present at any age, but most frequently presents in childhood

  • >70% cases occur before 5 y/o
  • ~30% cases first present in adulthood

Causes and Risk Factors

There is no single known cause of atopic eczema. It is a multifactorial condition involving genetic susceptibility, immune dysregulation, and environmental triggers. These factors contribute to a dysfunctional skin barrier, making the skin more prone to dryness, irritation, inflammation, and infection.

There is a strong genetic susceptibility

  • ~70% patients have a family history of atopy (e.g. atopic dermatitis, asthma, hay fever)
  • ~80% of children develop atopic dermatitis when both parents are affected; ~60% if one parent is affected
  • Filaggrin gene mutations are one of the most established genes involved in atopic dermatitis (thought to contribute to ~50% cases)

Clinical Features

Course and progression Atopic dermatitis typically follows an episodic course, with periods of flare-ups and remission.
Triggers Very common / broadly recognised triggers:

  • Heat and sweating
  • Cold / dry weather (atopic dermatitis is often worse in winter due to reduced humidity and dry skin, and improves in summer)
  • Irritants (e.g. soaps, detergents, fragrances, skincare products)
  • Skin infection (esp. Staphylococcus aureus)

More individual-specific triggers:

  • Contact allergens (e.g. metals, latex, perfumes)
  • Clothing material (e.g. synthetic fabrics, wool, silk)
  • Aeroallergens (e.g. pollen, animal dander, house dust mites)
  • Food triggers (e.g. cow’s milk, egg, wheat, soya, peanut and tree nuts)
Rash distribution The location and distribution of atopic dermatitis vary with age:

  • Infants
    • Primarily affects the facescalp, and extensor surfaces of the limbs
    • Nappy area is spared
    • Often affects the cheeks, but with relative sparing of the nose (“headlight sign”)
  • Children-onset disease and adults with long-standing disease (i.e. since childhood)
    • Primarily affects the flexural surfaces of the limbs (e.g. antecubital fossa, popliteal fossa)
  • Adult-onset disease
    • Generalised dryness and itching
    • Primary manifestation may affect the hands
Signs and symptoms The hallmark symptom is itching (the diagnosis is unlikely if there is no itch)

Acute flares may vary in appearance:

  • Increased itching and dryness
  • New or worsening erythema (often poorly demarcated)
  • Excoriation marks due to scratching
  • Bleeding, oozing, cracking of the skin

Secondary bacterial infection should be considered if there is weeping / honey-colour crusting / pustules / new pain + fever or malaise

Chronic eczema appearance:

  • Excoriation marks due to scratching
  • Lichenified skin (skin thickening from repeated scratching)
  • Follicular prominence / follicular papules
  • Dennie-Morgan folds (a crease / fold in the skin below the lower eyelid, associated with rubbing)

See the investigation and diagnosis section below for diagnostic criteria.

Complications

Infections are key acute complications of atopic dermatitis:

  • Staphylococcus aureus infection may present as impetigo or as an acute flare
  • HSV infection may present as grouped vesicles and punched-out erosions
  • Superficial fungal infections are more common

The most serious complication is eczema herpeticum – a potentially life-threatening disseminated HSV infection of eczematous skin (classically seen in patients with atopic dermatitis).

Features include:

  • Rapidly worsening, painful rash
  • Clusters of monomorphic vesicles and punched-out erosions
  • Haemorrhagic crusting
  • Widespread lesions that may coalesce into large, denuded or bleeding areas
  • Systemic toxicity e.g. fever, lymphadenopathy, and malaise

Atopic dermatitis also causes long-term psychosocial problems:

  • Sleep disturbance due to itching is a major implication, which can impair concentration, mood, and daytime functioning
  • Depression, anxiety
  • Reduced self-esteem and poor body image, which may affect social development and quality of life
  • Mainly seen in young children
    • Impact on school (e.g. time away from school, impaired performance, social restrictions, teasing, bullying)
    • Higher rates of behavioural problems, fearfulness, and dependency on parents

Investigation and Diagnosis

Atopic dermatitis is a clinical diagnosis

  • Investigations are NOT necessary for establishing a diagnosis
  • It is important to identify any triggers via a comprehensive history (NICE CKS explicitly noted to advise avoidance of over-the-counter tests, as these are of no proven value and most people do NOT need allergy testing)

Diagnostic Criteria

NICE outlined the following clinical diagnostic criteria:

  • Itchy skin, AND
  • At least 3 of the following:
    • Onset <2 y/o (this criterion should not be used in <4 y/o)
    • Visible flexural eczema involving the skin creases (or in ≤18 months: visible eczema on the cheeks and/or extensor areas)
    • Personal history of flexural eczema (or in ≤18 months: history of eczema on the cheeks and/or extensor areas)
    • Personal history of dry skin in the last 12 months.
    • Personal history of asthma or allergic rhinitis (or in <4 y/o: this criterion counts if there is family history of atopic disease in a first-degree relative)

NICE notes that these criteria apply to all ages, social classes, and ethnic groups. However, in children of Asian, black Caribbean, and black African ethnic groups, atopic eczema can affect the extensor surfaces rather than the flexures, and discoid (circular) or follicular (around the hair follicles) patterns may be more common.

Management

Conservative / General Management

For all patients, includes:

  • Trigger avoidance
  • Manage itch and scratching
  • Educate on flare recognition 

Severity Category

Category Appearance Psychological impact
Mild
  • Dry skin
  • Infrequent itching
  • +/- Small areas of redness
Little impact on everyday activities, sleep and psychosocial well-being

Sleep is unaffected

Moderate
  • Dry skin
  • Frequent itching
  • Redness +/- excoriation and skin thickening
Moderate impact on everyday activities, sleep and psychosocial well-being

Frequently disturbed sleep

Severe Widespread areas of dry skin with:

  • Incessant itching AND/OR
  • Redness +/- excoriation, extensive skin thickening, bleeding, oozing, cracking, alteration of pigmentation
Severe limitations of everyday activities and psychosocial functioning

Loss of sleep every night

Infected
  • Weeping, or
  • Crusting, or
  • Pustules, or
  • Fever / malaise
n/a

Pharmacological Management

The mainstay of atopic dermatitis management is frequent and liberal use of topical emollients. Emollients should be used in much larger quantities than other topical treatments (e.g. topical corticosteroids), typically by at least 10 times as much.

Brief overview:

Severity Management options
Mild
  • Regular emollient
  • Mild topical corticosteroid (e.g. hydrocortisone 1%)
Moderate
  • Regular emollient
  • Moderately potent topical corticosteroid (e.g. betamethasone valerate 0.025% or clobetasone butyrate 0.05%)
  • Maintenance: topical corticosteroid / calcineurin inhibitors
  • Medicated dressing / dry bandages
Severe
  • Regular emollient
  • Potent topical corticosteroid (betamethasone valerate 0.1%) +/- oral corticosteroids
  • Maintenance: topical corticosteroid / calcineurin inhibitors
  • Medicated dressing / dry bandages
  • Phototherapy
  • Systemic therapy (e.g. cyclosporin, azathioprine)

Mild Eczema

Flare management Consider a mild topical corticosteroid (e.g. hydrocortisone 1%) – to be continued for 48 hours after the flare is controlled

Continue regular emollient use – apply the steroid first, and wait for 15-30 min before applying the emollient

Maintenance therapy Advice on regular emollient use

  • A generous amount should be applied 4 times daily on the entire body (not just the affected skin)
  • Should be used even when symptoms are controlled

Active follow-up is rarely required for mild eczema, unless the person or carer requests it

Moderate Eczema

Flare management Moderately potent topical corticosteroid (e.g. betamethasone valerate 0.025% or clobetasone butyrate 0.05%) – to be continued for 48 hours after the flare is controlled

For delicate areas of skin (face and flexures):

  • Consider starting with a mild potency topical corticosteroid (e.g. hydrocortisone 1%)
  • Only increase to moderate potency if necessary, and aim for a maximum of 5 days use

Other topical therapies:

  • Continue emollients – apply the steroid first, and wait for 15-30 min before applying the emollient
  • Consider localised medicated dressings / dry bandages with emollients and topical corticosteroid for 7-14 days

If there is severe itch / urticaria:

  • Consider 1-month trial of non-sedating antihistamine (e.g. cetirizine, loratadine, fexofenadine)
  • If itching is affecting sleep: consider short course (maximum 2 weeks) of sedating antihistamine (e.g. chlorphenamine)
Maintenance therapy Advice on regular emollient use

  • A generous amount should be applied 4 times daily on the entire body (not just the affected skin)
  • Should be used even when symptoms are controlled

Consider preventive/maintenance treatment

  • 1st line: topical corticosteroid as ‘step down approach‘ or ‘intermittent treatment
  • 2nd line: topical calcineurin inhibitors (tacrolimus, pimecrolimus)
    • Only to be prescribed in secondary care
    • Only used in >2 y/o

Consider localised medicated dressings / dry bandages with emollients to treat areas of chronic lichenified skin

Severe Eczema

Flare management Potent topical corticosteroid (e.g. betamethasone valerate 0.1%) – to be continued for 48 hours after the flare is controlled

For delicate areas of skin (face and flexures):

  • Consider starting with a moderate potency topical corticosteroid (e.g. betamethasone valerate 0.025%, clobetasone butyrate 0.05%
  • Aiming for a maximum of 5 days of use

Other topical therapies:

  • Continue emollients – apply the steroid first, and wait for 15-30 min before applying the emollient
  • Consider localised medicated dressings / dry bandages with emollients and topical corticosteroid for 7-14 days
  • Consider oral corticosteroids (short-course) for severe, extensive eczema causing psychological distress

If there is severe itch / urticaria:

  • Consider 1-month trial of non-sedating antihistamine (e.g. cetirizine, loratadine, fexofenadine)
  • If itching is affecting sleep: consider short course (maximum 2 weeks) of sedating antihistamine (e.g. chlorphenamine)
Maintenance therapy Advice on regular emollient use

  • A generous amount should be applied 4 times daily on the entire body (not just the affected skin)
  • Should be used even when symptoms are controlled

Consider preventive/maintenance treatment

  • 1st line: topical corticosteroid as ‘step down approach‘ or ‘intermittent treatment
  • 2nd line: topical calcineurin inhibitors (tacrolimus, pimecrolimus)
    • Only to be prescribed by secondary care
    • Only used in >2 y/o

Consider localised medicated dressings / dry bandages with emollients to treat areas of chronic lichenified skin

Further secondary care options:

  • Phototherapy
  • Systemic immunosuppressants (e.g. cyclosporin, azathioprine)

Do NOT use potent corticosteroids in children under 12 months old, or very potent corticosteroids in children of any age, without specialist dermatological advice.

Infected Eczema

Admission to hospital is indicated if eczema herpeticum is suspected

  • Immediate treatment with IV aciclovir is necessary

DO NOT routinely offer topical / oral antibiotic for secondary bacterial infection of eczema, unless systemically unwell:

  • If antibiotic is offered, 1st line: flucloxacillin (alternative: clarithromycin)
  • For localised infection: consider topical fusidic acid

Episodes of infected eczema usually co-exist with a flare and will require concomitant treatment as described above.

Dry bandages and medicated dressings (including wet wrap therapy) should NOT be used to treat infected atopic eczema.

References


Related Articles

Impetigo

Contact Dermatitis

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.